Categories: CancerFinancialNews

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SANTA CRUZ, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) — Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today that BridgeBio Pharma, Inc. (Nasdaq: BBIO), has exercised its option to license macrocyclic peptide candidates discovered using UNP’s AI-enabled massively parallel chemistry platform.

This milestone signifies a significant milestone in the collaboration between the two companies, and reinforces the potential of macrocyclic peptides as a novel therapeutic modality for rare diseases and oncology. Macrocyclic peptides are a unique class of therapeutic compounds characterized by large, cyclic structures that offer significant advantages over traditional therapies such as small molecules and monoclonal antibodies. Their unique structure provides high stability, potent binding affinity, and the ability to access difficult-to-reach intracellular targets, positioning them as a promising therapeutic class.

“We are excited to see BridgeBio exercise its option, which marks a pivotal moment for both Unnatural Products and the field of macrocyclic peptide therapeutics,” said Cameron Pye, Ph.D., CEO and Co-Founder, Unnatural Products. “This collaboration deal highlights the growing recognition of macrocyclic peptides as a powerful new class of therapeutics. Our platform enables the design of peptides that can reach intracellular targets that have long been considered undruggable with conventional therapies, to address critical unmet medical needs in oncology and rare genetic diseases.”

Under the terms of the agreement, UNP assumed responsibility for research and preclinical development, and upon exercise, BridgeBio will assume responsibility for further preclinical and clinical development of the macrocyclic peptide candidates emerging from the collaboration. UNP received milestone payments for the progress of the research and option to license and will receive development and sales milestone payments as the program progresses, as well as tiered royalties upon commercialization.

UNP’s proprietary platform combines massively parallel chemistry with machine learning to design and optimize macrocyclic peptides. This approach enables the rapid generation of drug-like molecules capable of binding specific intracellular targets, including those involved in cancer and rare genetic diseases, which have traditionally been considered undruggable. The platform enables the development of peptides that are not only selective and potent but also orally bioavailable, overcoming one of the main limitations of peptide-based therapies that typically require injection.

About Unnatural Products, Inc.

Unnatural Products, Inc. (UNP), a California biotech company, has developed a platform that addresses the complexities of medicinal chemistry in the macrocycle space through a combination of parallel experimentation and machine learning. Founded by macrocycle pioneers whose academic work uncovered how Nature’s macrocycles work, UNP is developing a portfolio of therapeutic macrocycles against high-value and traditionally difficult-to-drug targets. For more information, visit www.unnaturalproducts.com.

For partnering opportunities, email: contact@unnaturalproducts.com.

Media Contact

Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Staff

Recent Posts

CORRECTION FROM THE SOURCE: FloraWorks Highlights New Study Showing CBN Reverses Cognitive Decline in Aging Mice

Peer-reviewed research published in Redox Biology supports the therapeutic potential of Cannabinol (CBN) in brain…

4 hours ago

RXST INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that the…

5 hours ago

Health-E Commerce® to Showcase flexible spending account (FSA) and health savings account (HSA) Engagement Tools at 38th Annual ECFC Symposium

FSA Store® and HSA Store® will demonstrate innovative e-commerce integrations, participant education resources, and compliance…

5 hours ago

Telemedicine Market to Reach USD 393.5 Billion by 2032, Driven by 15.1% CAGR | SkyQuest Technology Consulting

The telemedicine market is anticipated to increase due to the rising incidence of chronic diseases…

5 hours ago

Anywhere powered by Linus Health™ Expands Equitable Access to Early Detection of Cognitive Impairment

Fueled by successful community and clinical screenings, Linus Health brings its AI-powered remote cognitive assessment…

5 hours ago

Siemens Healthineers Receives Frost & Sullivan’s 2025 North America Company of the Year Award for Excellence in Advanced Visualization Applications

Recognized for delivering diagnostic innovation, workflow efficiency, and enterprise imaging leadership through advanced visualization solutions…

5 hours ago